Literature DB >> 23021562

Commentary on "comparative effectiveness of axitinib vs. sorafenib in advanced renal cell carcinoma (AXIS): a randomized phase 3 trial." B.I. Rini, B. Escudier, P. Tomczak, A. Kaprin, C. Szczylik, T.E. Hutson, M.D. Michaelson, V.A. Gorbunova, M.E. Gore, I.G. Rusakov, S. Negrier, Y.C. Ou, D. Castellano, H.Y. Lim, H. Uemura, J. Tarazi, D. Cella, C. Chen, B. Rosbrook, S. Kim, R.J. Motzer: Lancet 2011;378:1931-9 [Epub;2011, November 4].

Donald L Trump.   

Abstract

Entities:  

Year:  2012        PMID: 23021562     DOI: 10.1016/j.urolonc.2012.06.009

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


× No keyword cloud information.
  2 in total

1.  Targeted Therapy for Metastatic Renal Carcinoma: an Update.

Authors:  Rodrigo Donalisio da Silva; Diedra Gustafson; Leticia Nogueira; Priya N Werahera; Wilson R Molina; Fernando J Kim
Journal:  J Kidney Cancer VHL       Date:  2014-10-21

2.  Response to post-axitinib treatment in patients with metastatic renal cell carcinoma.

Authors:  Namita Chittoria; Housam Haddad; Paul Elson; Nizar M Tannir; Laura S Wood; Robert Dreicer; Jorge A Garcia; Brian I Rini; Eric Jonasch
Journal:  BMC Cancer       Date:  2016-03-29       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.